本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

BridgeBio Pharma, Inc.

54.36
-1.8950-3.37%
盘后54.360.00000.00%19:53 EDT
成交量:119.18万
成交额:6,532.88万
市值:103.92亿
市盈率:-13.28
高:56.50
开:56.21
低:54.29
收:56.26
52周最高:57.49
52周最低:21.72
股本:1.91亿
流通股本:1.51亿
量比:0.67
换手率:0.79%
股息:- -
股息率:- -
每股收益(TTM):-4.0935
每股收益(LYR):-2.8793
净资产收益率:-1789.67%
总资产收益率:-41.96%
市净率:-5.81
市盈率(LYR):-18.88

数据加载中...

2023/11/22

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/02

重要事件披露

Form 8-K - Current report
2023/11/02

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/09/25

重要事件披露

Form 8-K - Current report
2023/09/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/08/03

重要事件披露

Form 8-K - Current report
2023/08/03

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/07/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/07/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/07/17

重要事件披露

Form 8-K - Current report
2023/06/23

重要事件披露

Form 8-K - Current report
2023/05/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/04

重要事件披露

8-K - Current report
2023/05/04

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans